Volume : 08, Issue : 07, July – 2021
Title:
04.TO DETERMINE THE FREQUENCY OF PROSTATE CANCER IN PATIENTS OF SUSPICION OF PROSTATE CANCER
Authors :
Dr.Mehran Khan Lashari, Dr.Shehzad, Dr.Sunil Kumar, Dr.Imran Malik, Dr.Ahmed ullah, Dr.Faraj Mohsen Saleh Aboali, Dr.Mohsin Mustafa Memon, Prof.Manzoor Husain
Abstract :
Introduction: Prostate cancer is one of the most common malignancies in men whose prevalence increases with age. Due to its importance and prevalence, screening tests are performed annually after the age of 50 and even at lower ages in people with a positive family history (1, 2, 3). Screening methods for prostate cancer include digital rectal exam (DRE) and the prostate-specific antigen (PSA) blood test (1, 2).
Application of these methods leads to an early diagnosis of prostate cancer at lower clinical stages (1, 4).
In DRE test, stony hard prostate and nodularity are important for diagnosis of prostate cancer.
If prostate is hard and/or nodular, the patient is suspected of having prostate cancer, so PSA and TRUS-guided biopsy of prostate will follow (1). Although hardness and/or nodularity of prostate can be suspected, sometimes the examination findings are boarder line and cannot be used for a final diagnosis. PSA, a protein produced in prostate, is another means for prostate cancer diagnosis.
Objective: To determine the frequency of prostate cancer in patients of suspicion of prostate cancer.
Study Design: Descriptive Cross Sectional Study
Setting: This study was conducted at Department of Urology, Sindh Institute of Urology & Transplantation, Karachi, Pakistan.
Duration: Six months after the approval of synopsis from April 5, 2019 to
October 4, 2019.
Materials And Methods: All patients who fulfilled the inclusion criteria and visited to SIUT were included in the study. Informed consent was taken after explaining the procedure, risks and benefits of the study. Histologically adenocarcinomas that produced well defined, readily demonstrable gland patern glands are atypically smaller and are lined by uniform layer of cuboidal or columnar epithelium outer basal cell layer was absent cytoplasm of tumor cells were pale clear nuclei were large and often contain one or more large nucleoli mitotic figures were uncommon. All the collected data were entered into the performa attached at the end and used electronically for research purpose.
Results:
Mean ± SD of age, duration of symptoms and prostate volume were 63.8±7.14 years, 3.56±2.11 months and 54.7±21.60 ml respectively.
Prostate cancer was noted in 17 (16.8%) patients while 84 (83.2%) were found negative.
Conclusion:
It is to be concluded that the rate of prostate cancer was found to be noticeable in suspicion patients of prostate cancer. In present study majority of the patients presented with clinically advanced prostate cancers within a local clinical urologic practice.
Key words: Prostate, Cancer, Screening, Biopsy, Prostate Specific Antigen, BPH, Gleason Score, Rectal Examination, Transrectal Ultrasonography
Cite This Article:
Please cite this article in press Mehran et al., To Determine The Frequency Of Prostate Cancer In Patients Of Suspicion Of Prostate Cancer.., Indo Am. J. P. Sci, 2021; 08(07).
Number of Downloads : 10
References:
1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014; 65(1):124-37.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. Cancer. 2018; 68(1):7-30.
3. Teoh JY, Yuen SK, Tsu JH, Wong CK, Ho BS, Ng AT, et al. The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men. Asian J Androl. 2017; 19(1):113-7.
4. Al Rumaihi K, Al Jalham K, Younes N, Majzoub AA, Shokeir AA. The role of an abnormal prostate-specific antigen level and an abnormal digital rectal examination in the diagnosis of prostate cancer: A cross-sectional study in Qatar. Arab J Urol. 2013; 11(4):355-60.
5. Tadayon F, Arezegar HR, Khorrami MH, Juzdani RH, Shahdoost AA, Mellat M. Evaluation of prostatic cancer prevalence in patients with prostatic-specific antigen between 4 and 10 and normal digital rectal examination. Adv Biomed Res. 2016; 5:112.
6. Ishidoya S, Ito A, Orikasa K, Kawamura S, Tochigi T, Kuwahara M, et al. The outcome of prostate cancer screening in a normal Japanese population with PSA of 2-4 ng/ml and the free/total PSA under 12%. Jpn J Clin Oncol. 2008; 38(12):844-8.
7. Lee SE, Byun SS, Park HK, Shim HB, Ku JH. Detection of prostate cancer at low and intermediate serum prostate-specific antigen levels in a country with a low incidence of prostate cancer. Jpn J Clin Oncol. 2006; 36(6):376-80.
8. Teoh JY, Yuen SK, Tsu JH, Wong CK, Ho BS, Ng AT, et al. Prostate cancer detection upon transrectal ultrasound-guided biopsy in relation to digital rectal examination and prostate-specific antigen level: what to expect in the Chinese population?. Asian J Androl. 2015; 17(5):821-5.
9. Ries LA, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2004. National Cancer Institute, Bethesda, MD, based on November 2006 SEER data submission, posted to the SEER web site 2007. <http://seer.cancer.gov/csr/1975_ 2005/>.
10. AIHW (Australian Institute of Health and Welfare) & AACR (Australasian Association of Cancer Registries) 2007. Cancer in Australia: an overview, 2006. Cancer series no. 37 Cat. No. CAN 32, Canberra, AIHW.
11. American Cancer Society. Cancer Facts & Figures. Atlanta: American Cancer Society; 2010.
12. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006; 17:989–1003.
13. Wright ME, Bowen P, Virtamo J, Albanes D, Gann PH. Estimated phytanic acid intake and prostate cancer risk: a prospective cohort study. Int J Cancer 2012; 131:1396–406.
14. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, et al. Human prostate cancer risk factors. Cancer 2004; 101:2371–490.
15. Zeegers JA, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a metaanalysis. Cancer 2003; 97:1894–903.
16. Weaver RP, Noble MJ, Weigle JW. Correlation of ultrasound guided and digitally directed transrectal biopsies of palpable prostatic abnormalities. J Urol 1991; 145:516–8.
17. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142:71–
18. Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM, et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 2001; 165:1554–9.
19. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157:199–202.
20. Rodrı´ guez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol 1998; 160:2115–20.
21. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 2003; 16:95–101.
22. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino RC, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151:1283–90.
23. Crawford ED, Leewansangtong S, Goktas S, Holthaus K, Baier M. Efficiency of prostate- specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age- specific reference range as a cutoff for abnormal values. Prostate 1999; 38:296–302.
24. Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. Examination of the relationship between symptoms of prostatitis and histologic inflammation: baseline data from the REDUCE chemoprevention trial. J Urol 2007; 178:896–900.
25. Abdalla I, Ray P, Vaida F, Vijayakumar S. Racial differences in prostate-specific antigen levels and prostate-specific antigen densities in patients with prostate cancer. Am J Clin Oncol 1999; 22:537–41.
26. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6–4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277:1452.
27. Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar HA, Fritsche Jr HA. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 2001; 165:757.
28. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia HL, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or P4.0 ng per milliliter. N Engl J Med 2004; 350:2239–46.
29. Heidenreich APJ, Bastian J, Bellmunt M, Bolla S, Joniau MD, Mason V, et al. The updated EAU Guidelines on Prostate Cancer. 2012. Available at <http://www.uroweb.org/gls/pdf
/08%20Prostate%20Cancer_LR%20March%2013th%202012.